FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships Iterum Therapeutics' Orlynvah receives FDA approval for treating ...

Iterum Therapeutics (NASDAQ:ITRM) has announced during its third quarter 2024 earnings call the FDA approval of ORLYNVAH, an innovative oral treatment for uncomplicated urinary... -- ORLYNVAH ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat ...